Detrol is a drug owned by Upjohn Us 2 Llc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 25, 2012. Details of Detrol's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5382600 (Pediatric) | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Detrol is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Detrol's family patents as well as insights into ongoing legal events on those patents.
Detrol's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Detrol's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 25, 2012 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Detrol Generic API suppliers:
Tolterodine Tartrate is the generic name for the brand Detrol. 15 different companies have already filed for the generic of Detrol, with Unichem having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Detrol's generic
How can I launch a generic of Detrol before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Detrol's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Detrol's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Detrol -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 1 mg and 2 mg |
Alternative Brands for Detrol
There are several other brand drugs using the same active ingredient (Tolterodine Tartrate) as Detrol. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Upjohn |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tolterodine Tartrate, Detrol's active ingredient. Check the complete list of approved generic manufacturers for Detrol
About Detrol
Detrol is a drug owned by Upjohn Us 2 Llc. Detrol uses Tolterodine Tartrate as an active ingredient. Detrol was launched by Upjohn in 1998.
Approval Date:
Detrol was approved by FDA for market use on 25 March, 1998.
Active Ingredient:
Detrol uses Tolterodine Tartrate as the active ingredient. Check out other Drugs and Companies using Tolterodine Tartrate ingredient
Dosage:
Detrol is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG | TABLET | Prescription | ORAL |
| 2MG | TABLET | Prescription | ORAL |